NeuroOne Medical Technologies reported positive physician feedback from a study involving 25 epilepsy patients at the Mayo Clinic in Jacksonville, Florida.
Patients received treatment using the OneRF Ablation System. The procedure was well-tolerated and resulted in no serious long-term complications.
A majority of participants experienced significant reductions in seizure frequency. Some patients achieved sustained seizure freedom.
Most patients reported improved quality of life and treatment satisfaction. This real-world evidence supports a new diagnosis-to-therapy paradigm for drug-resistant focal epilepsy.